New patent expiration for Bristol Myers drug REYATAZ

Annual Drug Patent Expirations for REYATAZ Reyataz is a drug marketed by Bristol Myers Squibb and is included in two NDAs. It is available from six suppliers. There are two…
The post New patent expiration for Bristol Myers drug REYATAZ appeared f…


Celgene vs. Dr. Reddy’s Revlimid patent infringement case depends on polymorph stability; lack thereof may favor Celgene position – experts

This article was originally published on November 30th 2017 by Hamish McDougall and Alaric DeArment of BioPharm Insight, part of GlobalData. Polymorph differences support noninfringement argument Trace solvate amount could destabalise…
The post C…


Biotechblog